Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Feature
  • Published:

To selectivity and beyond

Nature Biotechnology volume 28, pages 1259–1266 (2010)Cite this article

Subjects

First-generation epigenetic drugs have proven clinically useful in several hematological cancers. But newer enzyme inhibitors in the pipeline aim to be more selective and promise to broaden the portfolio of therapeutic uses.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: The ever-expanding family of enzymes that control the structure of chromatin and gene transcription.
Figure 2: Making marks.
Figure 3: Programs in epigenetics by phase of development.

References

  1. Bostick, M. et al. Science 317, 1760–1764 (2007).

    Article  CAS  Google Scholar 

  2. Sooryanarayana, V. Nature 419, 624–629 (2002).

    Article  Google Scholar 

  3. Kondo, Y. et al. Nat. Genet. 40, 741–750 (2008).

    Article  CAS  Google Scholar 

  4. Matouk, I.J. et al. PLoS ONE 2, e845 (2007).

    Article  Google Scholar 

  5. Gupta, R.A. et al. Nature 464, 1071–1076 (2009).

    Article  Google Scholar 

  6. Herman, D. et al. Nat. Chem. Biol. 2, 551–558 (2006).

    Article  CAS  Google Scholar 

  7. Cui, H. et al. Science 299, 1753–1755 (2003).

    Article  CAS  Google Scholar 

  8. Jones, J.R. et al. Am. J. Med. Genet. A. 146A, 2213–2220 (2008).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. George S. Mack is a freelance writer based in Columbia, South Carolina.,

    George S Mack

Authors
  1. George S Mack
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mack, G. To selectivity and beyond. Nat Biotechnol 28, 1259–1266 (2010). https://doi.org/10.1038/nbt.1724

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.1724

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer